Close

BioXcel Therapeutics (BTAI) Reports FDA Acceptance of IND for BXCL501 for the Acute Treatment of Agitation

December 12, 2018 6:00 AM EST Send to a Friend
BioXcel Therapeutics, Inc. (NASDAQ: BTAI) today announced that the U.S. Food and Drug Administration (“FDA”), has accepted its Investigational New ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login